These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34108486)

  • 1. Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal storage disorders.
    De Risi M; Tufano M; Alvino FG; Ferraro MG; Torromino G; Gigante Y; Monfregola J; Marrocco E; Pulcrano S; Tunisi L; Lubrano C; Papy-Garcia D; Tuchman Y; Salleo A; Santoro F; Bellenchi GC; Cristino L; Ballabio A; Fraldi A; De Leonibus E
    Nat Commun; 2021 Jun; 12(1):3495. PubMed ID: 34108486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosomal storage of heparan sulfate causes mitochondrial defects, altered autophagy, and neuronal death in the mouse model of mucopolysaccharidosis III type C.
    Pshezhetsky AV
    Autophagy; 2016 Jun; 12(6):1059-60. PubMed ID: 25998837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competitive binding of extracellular accumulated heparan sulfate reduces lysosomal storage defects and triggers neuronal differentiation in a model of Mucopolysaccharidosis IIIB.
    De Pasquale V; Scerra G; Scarcella M; D'Agostino M; Pavone LM
    Biochim Biophys Acta Mol Cell Res; 2021 Oct; 1868(11):119113. PubMed ID: 34329663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
    King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice.
    Dwyer CA; Scudder SL; Lin Y; Dozier LE; Phan D; Allen NJ; Patrick GN; Esko JD
    Sci Rep; 2017 Apr; 7():46576. PubMed ID: 28418018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
    Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
    Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
    Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC
    J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
    Wilkinson FL; Holley RJ; Langford-Smith KJ; Badrinath S; Liao A; Langford-Smith A; Cooper JD; Jones SA; Wraith JE; Wynn RF; Merry CL; Bigger BW
    PLoS One; 2012; 7(4):e35787. PubMed ID: 22558223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine ameliorates mucopolysaccharidosis type IIIA.
    Capuozzo A; Montefusco S; Cacace V; Sofia M; Esposito A; Napolitano G; Nusco E; Polishchuk E; Pizzo MT; De Risi M; De Leonibus E; Sorrentino NC; Medina DL
    Mol Ther; 2022 Apr; 30(4):1432-1450. PubMed ID: 35121108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells.
    Keating DJ; Winter MA; Hemsley KM; Mackenzie KD; Teo EH; Hopwood JJ; Brooks DA; Parkinson-Lawrence EJ
    Neuroscience; 2012 Dec; 227():110-8. PubMed ID: 23022219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.
    McCarty DM; DiRosario J; Gulaid K; Killedar S; Oosterhof A; van Kuppevelt TH; Martin PT; Fu H
    Metab Brain Dis; 2011 Mar; 26(1):9-19. PubMed ID: 21225451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPS-IIIA mice acquire autistic behaviours with age.
    Lau AA; Tamang SJ; Hemsley KM
    J Inherit Metab Dis; 2018 Jul; 41(4):669-677. PubMed ID: 29520737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse.
    Paget TL; Parkinson-Lawrence EJ; Trim PJ; Autilio C; Panchal MH; Koster G; Echaide M; Snel MF; Postle AD; Morrison JL; Pérez-Gil J; Orgeig S
    Cells; 2021 Apr; 10(4):. PubMed ID: 33918094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic Disaccharide Standards Enable Quantitative Analysis of Stored Heparan Sulfate in MPS IIIA Murine Brain Regions.
    He QQ; Trim PJ; Lau AA; King BM; Hopwood JJ; Hemsley KM; Snel MF; Ferro V
    ACS Chem Neurosci; 2019 Aug; 10(8):3847-3858. PubMed ID: 31264853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous HSPC Transplantation Rescues Neuroinflammation and Ameliorates Peripheral Manifestations in the Mouse Model of Lysosomal Transmembrane Enzyme Deficiency, MPS IIIC.
    Pan X; Caillon A; Fan S; Khan S; Tomatsu S; Pshezhetsky AV
    Cells; 2024 May; 13(10):. PubMed ID: 38786099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.
    Derrick-Roberts A; Kaidonis X; Jackson MR; Liaw WC; Ding X; Ong C; Ranieri E; Sharp P; Fletcher J; Byers S
    Mol Genet Metab; 2020; 131(1-2):197-205. PubMed ID: 32739280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
    Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW
    Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosaminoglycans and mucopolysaccharidosis type III.
    Jakobkiewicz-Banecka J; Gabig-Ciminska M; Kloska A; Malinowska M; Piotrowska E; Banecka-Majkutewicz Z; Banecki B; Wegrzyn A; Wegrzyn G
    Front Biosci (Landmark Ed); 2016 Jun; 21(7):1393-409. PubMed ID: 27100513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucopolysaccharidosis (MPS IIIA) mice have increased lung compliance and airway resistance, decreased diaphragm strength, and no change in alveolar structure.
    Paget TL; Larcombe AN; Pinniger GJ; Tsioutsias I; Schneider JP; Parkinson-Lawrence EJ; Orgeig S
    Am J Physiol Lung Cell Mol Physiol; 2024 Jun; 326(6):L713-L726. PubMed ID: 38469649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.